Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INV441
- Development stage
- Preclinical
- Lead developer
- invIOs
- Modality
- Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, RNA Therapeutics → Nucleic Acid Therapeutics, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intratumoral
01
Overview
INV441 is an autologous cell therapy developed by invIOs that utilizes the EPiC platform to treat glioblastoma. The therapy involves isolating tumor-infiltrating lymphocytes (TILs) from the patient, modifying them ex vivo using siRNA to silence Cbl-b expression (an intracellular immune checkpoint), and then administering these modified TILs directly into the tumor. By inhibiting Casitas B-lineage lymphoma proto-oncogene B (Cbl-b), a negative regulator of T cell activation, INV441 aims to enhance local anti-tumor immune responses and promote tumor cell killing. This approach has demonstrated strong preclinical proof of concept in murine glioma models and is designed for rapid out-patient manufacturing with short vein-to-vein times. A first-in-human Phase 1 study in glioblastoma is planned for 2025 in collaboration with Dana-Farber Cancer Institute[1][3][7][8].
- Other names
- Cbl-b silenced autologous TIL therapyEPiC-TILs
02
Targets
CBLB (CBL-B)
Beyond the preview
Go deeper on INV441.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INV441.